Ebru YILMAZ, Nida DİNÇEL, İPEK KAPLAN BULUT, Sevgi MİR

Perıton Dıyalız Sıvıları

Periton diyalizi (PD) son dönem böbrek hastaları için önemli bir renal replasman tedavi yöntemidir. Hastalar evde uygulanan PD tedavisine kolayca uyum sağlarlar. Geleneksel standart periton diyaliz solüsyonları osmotic ajan olarak glukoz kullanırlar. Glukoz içeren diyaliz sıvıları yüksek konsantrasyonda glukoz içerirler. Laktat ve glukoz yıkım ürünlerinin oluşmasına neden olurlar. Yüksek osmolalite ve düşük pH'a sahiptirler. Tüm bu sayılan özellikler peritona zarar verir (fibrosis, neoanjiogenez). Yeni PD solüsyonları alternatif tampon sistemleri ve ozmotik ajan kullanırlar (ikodekstrin ve aminoasitler). Yüksek pH'ya sahip olup daha az glukoz yıkım ürünlerinin oluşumuna neden olurlar. Yeni PD solüsyonlarının kullanımı ile daha iyi metabolic kontrol ve vücut kompozisyonu sağlanabilir. Yeni solüsyonların kullanımı daha az fibrozise yol açar ve antiinflamatuvar özelliklerinden dolayı da periton zarı viabilitesini arttırırlar. Ama hasta sağ kalımını artırdıklarına dair kanıt yoktur. Bu derlemenin ile PD için kullanılan farklı tipte periton diyaliz sıvılarının tanımlaması ve gözden geçirilmesi amaçlanmıştır

Peritoneal Dialysis Solutions

Peritoneal dialysis (PD) is an important kidney replacement therapy for end stage renal disease (ESRD) patients. Patients easily adapt at home based treatment of PD. Standard traditional solutions uses glucose as an osmotic agent. Glucose based dialysis solutions contains high concentrations of glucose. They cause production of glucose degradation products and lactate. They have high osmolality, and low pH. All these features damage to the peritoneum by fibrosis and neoangiogenesis. Newer PD solutions were produced with alternative buffers and osmotic agents (icodextrin or amino acids). They have a higher pH and causes production of fewer glucose degradation products. With the usage of newer PD solutions we can achieve better metabolic controls of patients and body compositions. Peritoneal membrane viability increases by their less fibrotic and less inflammatory features of new solutions. But their effect on patient survival is not clearly identified yet. The aim of this review is to describe and to overview the different types of peritoneal dialysissolutions used during PD

PDF

___

Elvia Garcia-Lopez, Bengt Lindholm and Simon Davies. An Update on peritonel dialysis solutions. Nature rewiev Nephrology. 8,224-233 (2012).
Aroeira, L. S. et al. Epithelial to mesenchymal transition and peritoneal membrane failure in pe- ritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J. Am. Soc. Nephrol. 18, 2004-2013 (2007).
Boulanger, E. et al. The triggering of human pe- ritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol. Dial. Transplant. 19, 2208-2216 (2004).
Noh, H. et al. Oxidative stress during peritone- al dialysis: implications in functional and structural changes in the membrane. Kidney Int. 69, 2022- (2006).
Zeier, M. et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal ca- vity and enter the systemic circulation? Kidney Int. , 298-305 (2003).
Krediet, R. T. & Balafa, O. Cardiovascular risk in the peritoneal dialysis patient. Nat. Rev. Nephrol. 6, -460 (2010).
Ates¸, K. et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int. 60, 767-776 (2001).
Lee, H. Y. et al. Superior patient survival for con- tinuous ambulatory peritoneal dialysis patients tre- ated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit. Dial. Int. 25, 248-255 (2005).
Lee, H. Y. et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol. Dial. Transplant. 21, 2893-2899 (2006).
Posthuma, N. et al. Amadori albumin and ad- vanced glycation end-product formation in perito- neal dialysis using icodextrin. Perit. Dial. Int. 21, -51 (2001).
Ho dac Pannekeet, M. M. et al. Peritoneal transport characteristics with glucose polymer ba- sed dialysate. Kidney Int. 50, 979-986 (1996).
Garcia-Lopez, E. & Lindholm, B. Icodextrin me- tabolites in peritoneal dialysis. Perit. Dial. Int. 29, -376 (2009).
Mistry, C. D., Gokal, R. & Peers, E. A rando- mized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investiga- tion of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int. 46, 496-503 (1994).
Posthuma N, ter Wee PM, Donker AJM, Oe PL,van Dorp W, Peers EM, Verbrugh HA. Serum di- saccharides and osmolatilty in CCPD patients usind icodextrin or glucose as daytime dwell. Perit Dial Int ; 17:602-607.
Miller DJ, Dawnay A. Glycation of albumin with icodekstrin. Jam Soc Nephrol 1995;6:551.
Taylor, G. S., Patel, V., Spencer, S., Fluck, R. J. & McIntyre, C. W. Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continu- ous ambulatory peritoneal dialysis patients. Clin. Nephrol. 58, 445-450 (2002).
Jones, M. et al. Treatment of malnutrition with 1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. Am. J. Kidney Dis. , 761-769 (1998).
Dombros, N. et al. European best practice gui- delines for peritoneal dialysis. 5 Peritoneal dialysis solutions. Nephrol. Dial. Transplant. 20 (Suppl. 9), ix16-ix20 (2005).
Kopple K, Bernard D, Messana J, Swartz R Ber- gstrom J,Lindholm B, et l. Treatment of malnouris- hed CAPD patients with an aminoasit base dialysa- te. Kidney Int 1995; 47:1148-1157.
Shockley TR, Martis L, Tranaeus AP. New so- lutions forperitoneal dialyisis in adult and pediatric patients. Perit Dial Int 1999; 19 (Suppl 2) S23-26.
Boulanger, E. et al. The triggering of human pe- ritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol. Dial. Transplant. 19, 2208-2216 (2004).
Di Paolo, N., Garosi, G., Petrini, G. & Monaci, G. Morphological and morphometric changes in meso- thelial cells during peritoneal dialysis in the rabbit. Nephron 74, 594-599 (1996).
Ishibashi, Y. et al. Glucose dialysate induces mi- tochondrial DNA damage in peritoneal mesothelial cells. Perit. Dial. Int. 22, 11-21 (2002).
Catalan, M. P., Santamaría, B., Reyero, A., Or- tiz, A. & Egido, J. 3,4 di deoxyglucosone 3 ene pro- motes leukocyte apoptosis. Kidney Int. 68, 1303- (2005).
Kang, D. H. et al. High glucose solution and spent dialysate stimulate the synthesis of transfor- ming growth factor ?1 of human peritoneal meso- thelial cells: effect of cytokine costimulation. Perit. Dial. Int. 19, 221-230 (1999).
Ha, H., Yu, M. R. & Lee, H. B. High glucose-in- duced PKC activation mediates TGF ?1 and fibro- nectin synthesis by peritoneal mesothelial cells. Kidney Int. 59, 463-470 (2001).
Inagi, R. et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peri- toneal membranes in peritoneal dialysis. FEBS Lett. , 260-264 (1999).
Leung, J. C. et al. Glucose degradation produ- cts downregulate ZO 1 expression in human peri- toneal mesothelial cells: the role of VEGF. Nephrol. Dial. Transplant. 20, 1336-1349 (2005).
Perl, J., Nessim, S. J. & Bargman, J. M. The bi- ocompatibility of neutral pH, low-GDP peritoneal di- alysis solutions: benefit at bench, bedside, or both? Kidney Int. 79, 814-824 (2011).
Cho, J. H. et al. Impact of systemic and local pe- ritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1 year prospective study. Nephrol. Dial. Transplant. 25, -1973 (2010).
Mandl-Weber, S., Cohen, C. D., Haslinger, B., Kretzler, M. & Sitter, T. Vascular endothelial growth factor production and regulation in human peritone- al mesothelial cells. Kidney Int. 61, 570-578 (2002).
Pecoits-Filho, R. et al. Plasma and dialysate IL 6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol. Dial. Transplant. 17, 1480-1486 (2002).
van Esch, S. et al. Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients. Perit. Dial. Int. 24, 554- (2004).
Williams, J. D. et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis flu- id (balance) on the peritoneal membrane. Kidney Int. 66, 408-418 (2004).
Cooker, L. A. et al. Interleukin 6 levels decrease in effluent from patients dialyzed with bicarbonate/ lactate-based peritoneal dialysis solutions. Perit. Dial. Int. 21 (Suppl. 3), S102-S107 (2001).
Witowski, J. et al. Peritoneal dialysis with so- lutions low in glucose degradation products is as- sociated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol. Dial. Transplant. 19, 917-924 (2004).
Oh, K. H. et al. Intra-peritoneal interleukin 6 sys- tem is a potent determinant of the baseline perito- neal solute transport in incident peritoneal dialysis patients. Nephrol. Dial. Transplant. 25, 1639-1646 (2010).
Fusshoeller, A., Plail, M., Grabensee, B. & Plum, J. Biocompatibility pattern of a bicarbonate/ lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol. Dial. Transplant. 19, 2101-2106 (2004).
Martikainen, T. A., Teppo, A. M., Gronhagen-Ris- ka, C. & Ekstrand, A. V. Glucose-free dialysis so- lutions: inductors of inflammation or preservers of peritoneal membrane? Perit. Dial. Int. 25, 453-460 (2005).
Moriishi, M., Kawanishi, H., Watanabe, H. & Tsuchiya, S. Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane. Adv. Pe- rit. Dial. 21, 21-24 (2005).
Zareie, M. et al. Better preservation of the peri- toneum in rats exposed to amino acid-based perito- neal dialysis fluid. Perit. Dial. Int. 25, 58-67 (2005).
De Boer AW, Schroder CH, van Vlict R, Willcms JL,Monnenes LAH. Clinical exprience with icodext- rin in children: ultrafiltration profiles and metabo- lism. Pediatr Nephrol 2000; 15: 21-24.
Peers EM, Scrimgeour AC, Haycox AR. Cost- containment in CAPD patients with ultrafiltration fai- lure. Clin Drug Invest 1995; 10: 53-58.
Szeto, C. C. et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glu- cose-degradation products--a 1 year randomized control trial. Nephrol. Dial.
Stenvinkel, P. et al. Strong association betwe- en malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 55, 1899-1911 (1999).
Park, S. H. et al. Effects of neutral pH and low-glucose degradation product-containing peri- toneal dialysis fluid on systemic markers of inflam- mation and endothelial dysfunction: a randomized controlled 1 year follow-up study. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfr451.
Welten, A. G. et al. Single exposure of me- sothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-produ- cts (AGEs) and a proinflammatory response. Perit. Dial. Int. 23, 213-221 (2003).
Krediet, R. T. & Balafa, O. Cardiovascular risk in the peritoneal dialysis patient. Nat. Rev. Nephrol. 6, -460 (2010).
Prinsen, B. H. et al. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peri- toneal dialysis. Kidney Int. 65, 1064-1075 (2004).
Floré, K. M. & Delanghe, J. R. Analytical interfe- rences in point of care testing glucometers by ico- dextrin and its metabolites: an overview. Perit. Dial. Int. 29, 377-383 (2009).
Babazono, T. et al. Effects of icodextrin on gly- cemic and lipid profiles in diabetic patients undergo- ing peritoneal dialysis. Am. J. Nephrol. 27, 409-415 (2007).
Paniagua, R. et al. Icodextrin improves meta- bolic and fluid management in high and high-ave- rage transport diabetic patients. Perit. Dial. Int. 29, -432 (2009).
de Jager, D. J. et al. Cardiovascular and noncar- diovascular mortality among patients starting dialy- sis. JAMA 302, 1782-1789 (2009).
Fusshoeller, A., Plail, M., Grabensee, B. & Plum, J. Biocompatibility pattern of a bicarbonate/ lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol. Dial. Transplant. 19, 2101-2106 (2004).
Pajek, J. et al. Short-term effects of a new bicar- bonate/lactate-buffered and conventional peritone- al dialysis fluid on peritoneal and systemic inflam- mation in CAPD patients: a randomized controlled study. Perit. Dial. Int. 28, 44-52 (2008).
Posthuma, N. et al. Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD pa- tients. Perit. Dial. Int. 19, 334-342 (1999).
Gokal, R., Mistry, C. D. & Peers, E. M. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis. Perit. Dial. Int. 15, 226-230 (1995).
Davies, S. J. l carnitine: more than just an alter- native to glucose as an osmotic agent for peritoneal dialysis? Kidney Int. 80, 565-566 (2011).